CE InformationDownload MaterialsCourse Progress
  • Access Webinar
  • Evaluation
  • Certificate
Evaluation

Taking a Closer Look at S1P Receptor Modulators in Ulcerative Colitis: Practical Considerations and Optimal Positioning

Evaluation

HMP Education would appreciate your feedback on the quality and impact of this activity.

Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little).

To what extent are you able to better achieve each of the following learning objectives?

Describe the mechanism of action and clinical role for S1PR modulators in the management of UC
Evaluate the most recent safety and efficacy data associated with current and emerging S1PR modulators
Outline patient-centered and practical considerations to tailor care and address adverse events

Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor).

Stephen B. Hanauer, MD, MACG
Christina Y. Ha, MD, FACG, AGAF
Adam Cheifetz, MD

Please rate the following components relating to this activity:

Content
Relevance to your practice 
Educational format 
Audience-participation portions (eg., Q&A, polling, pre/post-testing) 
Resources and/or other materials supporting the activity
Overall

Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices.
How many patients do you encounter with UC on a weekly basis?

Do you feel like there were any new data presented?

Did you learn anything new?

Did you gain confidence on the new information?

Did this program include opportunities to learn as a part of a healthcare team?
Sphingosine-1 receptor (S1PR) modulators mitigate ulcerative colitis (UC) pathogenesis through which mechanism?
Data from the TRUE NORTH study demonstrated that 37% of patients treated with ______ maintained clinical remission.
Based on current data, S1PR modulators are potentially best positioned for:
How confident are you now in your ability to appropriately utilize S1PR modulators and manage/mitigate AEs in clinical practice?
How confident are you now in your ability to manage/mitigate potential AEs associated with S1PR modulators in clinical practice?

Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific.
What challenges or barriers outside of your control may prevent you from changing your practice?
255 characters max

The information presented in this activity did not serve to advance a proprietary interest of any commercial entity.
Based on my participation in this activity, I anticipate I will more often (select all that apply):